Lack of early symptom improvement is not predictive of final responder statusMALVERN, Pa., April 10, 2024 (GLOBE NEWSWIRE) -- Neuronetics,…
VANCOUVER, British Columbia, April 10, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that…
HAYWARD, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused,…
ROCKVILLE, Md., April 08, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and…
Clinical Data from Multiple Trials Showed Improvements in Both Motor and Non-Motor SymptomsJERUSALEM and BURLINGTON, Mass., April 04, 2024 (GLOBE…
IRVINE, Calif., March 30, 2024 (GLOBE NEWSWIRE) -- Regarding a release issued under the same headline on March 29, 2024…
Collaborative Study involving the VA and UCSD achieved statistically significant decrease in PCS and PTSD symptoms versus control group The…
Data Published in Leading Peer-Reviewed Publication, Journal of Clinical MedicineJERUSALEM and BURLINGTON, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- BrainsWay…
SPARKS, NV / ACCESSWIRE / March 27, 2024 / Ludwig Enterprises, Inc, (OTC PINK:LUDG): A US-based biotechnology company is pleased…
NeuroStar is the first and only TMS therapy cleared as an adjunct treatment for patients ages 15 and olderMALVERN, Pa.,…